Your session is about to expire
← Back to Search
Oral Immunotherapy for Peanut Allergy
Study Summary
This trial will observe the outcomes of oral immunotherapy for peanut allergy, collecting blood samples and participant-reported data.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 37 Patients • NCT00932828Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was referred by an MGH allergist for food allergy treatment.I am currently taking beta blocker medication.I or my child have a confirmed peanut allergy through tests or history.I am pregnant, planning to become pregnant, or breastfeeding.I am between 6 months and 65 years old with a peanut allergy.I am willing to sign the consent form if I am of the required age.I was referred by an MGH allergist for food allergy treatment.My asthma is severe or not well-controlled.I have severe health issues like autoimmune or chronic inflammatory conditions.I am willing to sign the consent form if I am of the appropriate age.
- Group 1: active peanut OIT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical trial accommodate individuals aged fifty or above?
"According to this trial's eligibility requirements, the oldest possible participant is 65 years old and the youngest must be at least 6 months of age."
Is enrollment still available for this clinical research endeavor?
"This investigation, which was started on June 25th 2020 and last updated May 3rd 2021 is not currently enrolling participants. However, there are 259 other clinical investigations actively recruiting at this moment in time."
How risky is Peanut oral immunotherapy for individuals?
"While there is no data supporting the efficacy of peanut oral immunotherapy, there are safety studies already conducted that earned this drug a score of 2."
Would I be considered a suitable participant in this research?
"This peanut allergy trial is searching for 500 participants between the ages of 6 months and 65 years. In addition to meeting these age requirements, potential patients must also be willing to sign an assent form (if applicable)."
Share this study with friends
Copy Link
Messenger